prodrug medic compound administr metabol ie convert within bodi pharmacolog activ drug instead administ drug direct correspond prodrug use improv drug absorb distribut metabol excret adm prodrug often design improv bioavail drug poor absorb gastrointestin tract prodrug may use improv select drug interact cell process intend target reduc advers unintend effect drug especi import treatment like chemotherapi sever unintend undesir side effect compound undergo biotransform exhibit pharmacolog effect note modifi ref note prodrug thus view drug contain special nontox protect group use transient manner alter elimin undesir properti parent molecul mani herbal extract histor use medicin contain glycosid sugar deriv activ agent hydrolyz intestin releas activ bioavail aglycon exampl salicin dglucopyranosid cleav esteras releas salicyl acid aspirin acetylsalicyl acid first make felix hoffmann bayer synthet prodrug salicyl acid howev case codein morphin administ drug enzymat activ form sugar deriv morphineglucuronid activ parent compound first synthet antimicrobi drug arsphenamin discov sahachiro hata laboratori paul ehrlich toxic bacteria convert activ form bodi likewis prontosil first sulfa drug discov gerhard domagk must cleav bodi releas activ molecul sulfanilamid sinc time mani exampl identifi terfenadin first nonsed antihistamin withdraw market small risk serious side effect howev terfenadin discov prodrug activ molecul fexofenadin carri risk parent compound therefor fexofenadin could place market safe replac origin drug loratadin anoth nonsed antihistamin prodrug desloratadin larg respons antihistaminerg effect parent compound howev case parent compound side effect associ terfenadin loratadin activ metabolit desloratadin current market approxim market drug worldwid consid prodrug sinc least prodrug approv fda seven prodrug approv six exampl recent approv prodrug dabigatran etexil approv gabapentin enacarbil sofosbuvir tedizolid phosphat isavuconazonium aripiprazol lauroxil selexipag latanoprosten bunod benzhydrocodon tozinameran prodrug classifi two major type base bodi convert prodrug final activ drug form major type far categor subtyp base factor type whether intracellular bioactiv locat also site therapeut action type whether bioactiv occur gastrointestin fluid circul system type ia prodrug includ mani antimicrobi chemotherapi agent eg flurouracil type ib agent reli metabol enzym especi hepat cell bioactiv prodrug intracellular activ drug type ii prodrug bioactiv extracellular either milieu gi fluid type iia within system circul andor extracellular fluid compart type iib near therapeut target tissuescel type iic reli common enzym esteras phosphatas target direct enzym import prodrug belong multipl subtyp ie mixedtyp mixedtyp prodrug one bioactiv multipl site either parallel sequenti step exampl prodrug bioactiv concurr target cell metabol tissu could design type iaib prodrug eg hmg coa reductas inhibitor chemotherapi agent note symbol appli prodrug bioactiv sequenti exampl initi gi fluid system within target cell design type iiaia prodrug eg tenofovir disoproxil note symbol appli mani antibodi virus genedirect enzym prodrug therapi adept vdept gdept propos nanoparticl nanocarrierlink drug understand sequenti mixedtyp prodrug differenti two subtyp symbol dash use design indic sequenti step bioactiv mean distinguish symbol slash use parallel mixedtyp prodrug